Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ASP0113 for prevention of CMV complications after allogeneic hematopoietic cell transplant
2013-000903-18Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- May 2013
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing ASP0113 with Placebo (2 arms). Primary endpoint: Composite of overall mortality and CMV end-organ disease through 1 year post-transplant. Started May 2013; status: completed.
02
Drugs
ASP0113
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2013-000903-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000903-18.